Texas Yale Capital Corp’s AbbVie ABBV Stock Holding History

Texas Yale Capital Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.2M	Buy	47,107 +160	+0.3%	+$35.5K	0.29%	48
2025 Q4	$10.7M	Buy	46,947 +4,208	+10%	+$959K	0.33%	42
2025 Q3	$9.9M	Buy	42,739 +841	+2%	+$171K	0.31%	44
2025 Q2	$7.78M	Buy	41,898 +3,890	+10%	+$723K	0.25%	55
2025 Q1	$7.96M	Buy	38,008 +63	+0.2%	+$12.2K	0.33%	49
2024 Q4	$6.74M	Sell	37,945 -453	-1%	-$83.3K	0.27%	56
2024 Q3	$7.58M	Hold	38,398	–	–	0.33%	52
2024 Q2	$6.59M	Sell	38,398 -350	-0.9%	-$58K	0.31%	54
2024 Q1	$7.06M	Buy	38,748 +50	+0.1%	+$8.62K	0.31%	51
2023 Q4	$6M	Buy	38,698 +4,901	+15%	+$715K	0.29%	57
2023 Q3	$5.04M	Sell	33,797 -300	-0.9%	-$44K	0.23%	58
2023 Q2	$4.59M	Buy	34,097 +550	+2%	+$80.7K	0.22%	71
2023 Q1	$5.35M	Hold	33,547	–	–	0.27%	59
2022 Q4	$5.42M	Buy	33,547 +100	+0.3%	+$15.3K	0.31%	53
2022 Q3	$4.49M	Sell	33,447 -175	-0.5%	-$25.1K	0.29%	58
2022 Q2	$5.15M	Buy	33,622 +275	+0.8%	+$42K	0.33%	52
2022 Q1	$5.41M	Buy	33,347 +120	+0.4%	+$17.4K	0.29%	68
2021 Q4	$4.5M	Buy	33,227 +545	+2%	+$64.4K	0.23%	82
2021 Q3	$3.52M	Buy	32,682 +260	+0.8%	+$29.7K	0.2%	96
2021 Q2	$3.65M	Buy	32,422 +330	+1%	+$37.2K	0.21%	91
2021 Q1	$3.47M	Buy	32,092 +122	+0.4%	+$13K	0.22%	89
2020 Q4	$3.43M	Buy	31,970 +250	+0.8%	+$24K	0.23%	90
2020 Q3	$2.78M	Sell	31,720 -14	-0%	-$1.32K	0.21%	99
2020 Q2	$3.12M	Buy	31,734 +1,877	+6%	+$165K	0.25%	86
2020 Q1	$2.27M	Hold	29,857	–	–	0.22%	99
2019 Q4	$2.64M	Sell	29,857 -690	-2%	-$57.3K	0.18%	111
2019 Q3	$2.31M	Hold	30,547	–	–	0.17%	118
2019 Q2	$2.22M	Sell	30,547 -30,547	-50%	-$2.4M	0.17%	117
2019 Q1	$4.92M	Buy	61,094 +30,547	+100%	+$2.5M	0.2%	107
2018 Q4	$2.82M	Sell	30,547 -1,421	-4%	-$125K	0.25%	84
2018 Q3	$3.02M	Buy	31,968 +585	+2%	+$55.5K	0.24%	91
2018 Q2	$2.91M	Sell	31,383 -325	-1%	-$31.7K	0.25%	85
2018 Q1	$3M	Hold	31,708	–	–	0.26%	73
2017 Q4	$3.07M	Buy	31,708 +2,125	+7%	+$200K	0.26%	73
2017 Q3	$2.63M	Sell	29,583 -475	-2%	-$36.2K	0.23%	83
2017 Q2	$2.18M	Buy	30,058 +150	+0.5%	+$10.1K	0.19%	97
2017 Q1	$1.95M	Hold	29,908	–	–	0.17%	106
2016 Q4	$1.87M	Hold	29,908	–	–	0.18%	110
2016 Q3	$1.89M	Hold	29,908	–	–	0.18%	108
2016 Q2	$1.85M	Hold	29,908	–	–	0.18%	114
2016 Q1	$1.71M	Hold	29,908	–	–	0.18%	112
2015 Q4	$1.77M	Hold	29,908	–	–	0.17%	112
2015 Q3	$1.63M	Hold	29,908	–	–	0.15%	120
2015 Q2	$2.01M	Hold	29,908	–	–	0.17%	112
2015 Q1	$1.75M	Sell	29,908 -2,665	-8%	-$161K	0.14%	124
2014 Q4	$2.13M	Buy	32,573 +5,534	+20%	+$349K	0.18%	92
2014 Q3	$1.56M	Buy	27,039 +6,989	+35%	+$388K	0.15%	107
2014 Q2	$1.13M	Hold	20,050	–	–	0.14%	133
2014 Q1	$1.03M	Buy	20,050 +6,915	+53%	+$349K	0.14%	134
2013 Q4	$694K	Buy	13,135 +50	+0.4%	+$2.46K	0.11%	148
2013 Q3	$585K	Buy	13,085 +4,605	+54%	+$204K	0.1%	164
2013 Q2	$351K	Buy	+8,480	New	+$371K	0.06%	210

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Texas Yale Capital Corp's ABBV Position: Q1 2026 in Review

Texas Yale Capital Corp increased its AbbVie (ABBV) stake by 0.34% in Q1 2026, buying an estimated $35.5K and bringing the position to 47,107 shares worth $10.2M. The position accounts for 0.29% of the portfolio, ranked #48.

Texas Yale Capital Corp first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.7M in Q4 2025. 4,074 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Texas Yale Capital Corp held 47,107 shares of AbbVie worth $10.2M as of Q1 2026.
Texas Yale Capital Corp bought 160 AbbVie shares in Q1 2026, an estimated $35.5K.
AbbVie made up 0.29% of Texas Yale Capital Corp's portfolio in Q1 2026, its #48 holding.
Texas Yale Capital Corp first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Texas Yale Capital Corp's AbbVie position peaked at $10.7M in Q4 2025.
4,074 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.